KR20150024919A - 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 - Google Patents

크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 Download PDF

Info

Publication number
KR20150024919A
KR20150024919A KR20157001953A KR20157001953A KR20150024919A KR 20150024919 A KR20150024919 A KR 20150024919A KR 20157001953 A KR20157001953 A KR 20157001953A KR 20157001953 A KR20157001953 A KR 20157001953A KR 20150024919 A KR20150024919 A KR 20150024919A
Authority
KR
South Korea
Prior art keywords
renal
rats
group
substituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157001953A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 레이드마처
파트리샤 맥도날드
Original Assignee
다케다 파마슈티칼스 유에스에이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 파마슈티칼스 유에스에이, 인코포레이티드 filed Critical 다케다 파마슈티칼스 유에스에이, 인코포레이티드
Publication of KR20150024919A publication Critical patent/KR20150024919A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR20157001953A 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 Ceased KR20150024919A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85850906P 2006-11-13 2006-11-13
US60/858,509 2006-11-13
PCT/US2007/084573 WO2008064015A1 (en) 2006-11-13 2007-11-13 Methods for preserving renal function using xanthine oxidoreductase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012310A Division KR20090103879A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167005469A Division KR20160031040A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Publications (1)

Publication Number Publication Date
KR20150024919A true KR20150024919A (ko) 2015-03-09

Family

ID=39430048

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097012310A Ceased KR20090103879A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
KR20157001953A Ceased KR20150024919A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
KR1020167005469A Ceased KR20160031040A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097012310A Ceased KR20090103879A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167005469A Ceased KR20160031040A (ko) 2006-11-13 2007-11-13 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Country Status (11)

Country Link
US (1) US20080269226A1 (enExample)
EP (1) EP2101761A4 (enExample)
JP (3) JP2010509372A (enExample)
KR (3) KR20090103879A (enExample)
CN (1) CN101677999A (enExample)
AU (1) AU2007323919A1 (enExample)
BR (1) BRPI0718611A2 (enExample)
CA (1) CA2669935A1 (enExample)
MX (1) MX2009004984A (enExample)
RU (1) RU2508099C2 (enExample)
WO (1) WO2008064015A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
BR112012032033A2 (pt) 2010-06-16 2017-10-31 Takeda Pharmaceuticals Usa Inc novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
US20130109726A1 (en) * 2010-06-25 2013-05-02 Teijin Pharma Limited Sustained-release therapeutic agent for hypertension and renal dysfunction
CN102372679A (zh) * 2010-08-27 2012-03-14 北京润德康医药技术有限公司 一种非布司他水溶性衍生物及其制备方法
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
JP5862897B2 (ja) * 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
CN102757403B (zh) * 2011-04-27 2015-04-29 浙江九洲药业股份有限公司 一种非布索坦衍生物及其制备方法
TW201328692A (zh) * 2011-10-11 2013-07-16 Univ Osaka 脫髓鞘疾病之治療劑及預防劑
TW201334779A (zh) 2012-01-27 2013-09-01 Teijin Pharma Ltd 糖尿病的治療藥
WO2014065275A1 (ja) * 2012-10-23 2014-05-01 国立大学法人福井大学 腫瘍融解症候群の治療薬及び予防薬
CN103265636B (zh) * 2013-05-23 2015-09-16 中国药科大学 一种具有降血糖作用的新型肽
CN104548066A (zh) * 2015-01-19 2015-04-29 中国药科大学 一种具有降血糖作用的新型肽的新用途
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬
CN106279024B (zh) * 2016-07-19 2018-09-14 华南理工大学 一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
KR20230119303A (ko) * 2022-02-07 2023-08-16 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) * 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2727802A1 (de) * 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH0366669A (ja) * 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
JP2725886B2 (ja) * 1990-11-30 1998-03-11 帝人株式会社 ２―アリールチアゾール誘導体及びその医薬組成物
US5358961A (en) * 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5514681A (en) * 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US6037344A (en) * 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5770601A (en) * 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) * 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
CA2190993C (en) * 1995-04-07 2004-06-01 Mikio Ota Protective agent for organ or tissue
ID21775A (id) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) * 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
EP1044002A4 (en) * 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
CZ298170B6 (cs) * 1998-06-19 2007-07-11 Teijin Limited Polymorfní a amorfní modifikace 2-(3-kyan-4-isobutoxyfenyl)-4-methyl-5-thiazolkarboxylové kyseliny a zpusob jejich prípravy
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
US7799794B2 (en) * 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
EP1416942B1 (en) * 2001-04-18 2007-12-12 Genzyme Corporation Amine polymers for treating gout and binding uric acid
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
RU2293733C2 (ru) * 2002-01-28 2007-02-20 Фуджи Якухин Ко., Лтд. Новые 1,2,4-триазольные соединения, способы их получения и содержащие их лекарственные средства
SI1488790T1 (sl) * 2002-03-28 2014-09-30 Teijin Pharma Limited Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) * 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
EP1819334A1 (en) * 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US20070167454A1 (en) * 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CA2812034C (en) * 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat

Also Published As

Publication number Publication date
CN101677999A (zh) 2010-03-24
AU2007323919A1 (en) 2008-05-29
BRPI0718611A2 (pt) 2014-02-25
KR20090103879A (ko) 2009-10-01
US20080269226A1 (en) 2008-10-30
EP2101761A1 (en) 2009-09-23
JP6233899B2 (ja) 2017-11-22
JP2014012726A (ja) 2014-01-23
WO2008064015A1 (en) 2008-05-29
MX2009004984A (es) 2009-09-23
KR20160031040A (ko) 2016-03-21
JP2010509372A (ja) 2010-03-25
RU2009122505A (ru) 2010-12-20
CA2669935A1 (en) 2008-05-29
RU2508099C2 (ru) 2014-02-27
JP2016188231A (ja) 2016-11-04
EP2101761A4 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
KR20150024919A (ko) 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20130143886A1 (en) Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
US20140329868A1 (en) Methods for treating hypertension
JP2010516691A (ja) 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法
CN104023723B (zh) 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
CN105939728A (zh) 用于治疗和预防肾病和脂肪肝病的方法
US20130012553A1 (en) Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors
KR20210100594A (ko) 염증성 장애의 치료에 사용하기 위한 벤조이미다졸 유도체
MX2008000779A (es) Uso de activadores y estimuladores de guanilatociclasa solubles para la prevencion o tratamiento de trastornos renales.
KR20210150436A (ko) 화학식 (i)의 화합물 및 glp-1 수용체 효현제를 포함하는 병용 요법
WO2002026231A1 (en) Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
KR101846096B1 (ko) 베타-카볼린 알칼로이드의 크산틴 옥시다제 활성 억제 용도
Brooks et al. Vasopressin and the pathogenesis of chronic renal failure
Dyson et al. The nitrite reductase activity of xanthine oxidoreductase sustains cardiovascular health
JP2024513502A (ja) Ｕｒａｔ１阻害剤、医薬組成物及びその使用
US20080317728A1 (en) Lowering Uric Acid to Prevent or Accelerate Recovery of Acute Renal Failure
MXPA96002577A (en) Treatment of arterioesclerosis and xant
ZA200404808B (en) Chalcone derivatives and their use to treat diseases.

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160229

Effective date: 20160411

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20160411

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2015 7001953

Appeal request date: 20160229

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016101001255

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000